TRAIL-induced cytotoxicity in a melphalan-resistant rhabdomyosarcoma cell line via activation of caspase-2

Anticancer Research

Volumn 26, Issue 1 A, 2006, Pages 351-356

  Kluttermann K ^a   Banning, U ^a   Kachel, M ^a   Krause, C ^a   Korholz D ^a   Mauz Korholz C ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Caspase 2; Drug resistance; Rhabdomyosarcoma; TRAIL induced apoptosis

Indexed keywords

BENZYLOXYCARBONYLVALYLASPARTYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE 2; CASPASE 3; CASPASE 8; CASPASE INHIBITOR; MELPHALAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL STRAIN TE 671; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; RHABDOMYOSARCOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS REGULATORY PROTEINS; CASPASE 2; CASPASES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME ACTIVATION; HUMANS; ISOENZYMES; MELPHALAN; MEMBRANE GLYCOPROTEINS; RHABDOMYOSARCOMA; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 32144456063     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Pappo AS and Shapiro DN: Rhabdomyosarcoma: biology and therapy. Cancer Treat Res 92: 309-339, 1997.
2. Dagher R and Helman L: Rhabdomyosarcoma: an overview. Oncologist 4: 34-44, 1999.
3. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC and Lynch DH: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163, 1999.
4. Griffith TS, Chin WA, Jackson GC, Lynch DH and Kubin MZ: Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 161: 2833-2840, 1998.
5. Petak I, Douglas L, Tillman DM, Vernes R and Houghton JA: Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis. Clin Cancer Res 6: 4119-4127, 2000.
6. Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R, Hideshima T and Anderson KC: TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98: 795-804, 2001.
7. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A and Ashkenazi A: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271: 12687-12690, 1996.
8. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682, 1995.
9. Ashkenazi A and Dixit VM: Death receptors: signaling and modulation. Science 281: 1305-1308, 1998.
10. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z and Schwall R: H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162, 1999.
11. LeBlanc HN and Ashkenazi A: Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10: 66-75, 2003.
12. Boatright KM, Renatus M, Scott FL, Sperandio S, Shin H, Pedersen IM, Ricci JE, Edris WA, Sutherlin DP, Green DR, and Salvesen GS: A unified model for apical caspase activation. Mol Cell 11: 529-541, 2003.
13. Stennicke HR and Salvesen GS: Caspases - controlling intracellular signals by protease zymogen activation. Biochim Biophys Acta 1477: 299-306, 2000.
14. Budihardjo I, Oliver H, Lutter M, Luo X and Wang X: Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 15: 269-290, 1999.
15. Wagner KW, Engels IH and Deveraux QL: Caspase-2 can function upstream of bid cleavage in the TRAIL apoptosis pathway. J Biol Chem 279: 35047-35052, 2004.
16. Creagh EM, Conroy H and Martin SJ: Caspase-activation pathways in apoptosis and immunity. Immunol Rev 193: 10-21, 2003.
17. McAllister RM, Isaacs H, Rongey R, Peer M, Au W, Soukup SW and Gardner MB: Establishment of a human medulloblastoma cell line. Int J Cancer 20: 206-212, 1977.
18. Chen TR, Dorotinsky C, Macy M and Hay R: Cell identity resolved. Nature 340: 106, 1989.
19. Stratton MR, Reeves BR and Cooper CS: Misidentified cell. Nature 337: 311-312, 1989.
20. Mauz-Korholz C, Kachel M, Harms-Schirra B, Klein-Vehne A, Tunn PU and Korholz D: Drug-induced caspase-3 activation in a Ewing tumor cell line and primary Ewing tumor cells. Anticancer Res 24: 145-149, 2004.
21. Lazarus HM, Herzig RH, Graham-Pole J, Wolff SN, Phillips GL, Strandjord S, Hurd D, Forman W, Gordon EM, Coccia P et al: Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol 1: 359-367, 1983.
22. Hazlehurst LA, Enkemann SA, Beam CA, Argilagos RF, Painter J, Shain K H, Saporta S, Boulware D, Moscinski L, Alsina M and Dalton WS: Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res 63: 7900-7906, 2003.
23. Matsura T, Kai M, Jiang J, Babu H, Kini V, Kusumoto C, Yamada K and Kagan VE: Endogenously generated hydrogen peroxide is required for execution of melphalan-induced apoptosis as well as oxidation and externalization of phosphatidylserine. Chem Res Toxicol 17: 685-696, 2004.
24. Fulda S, Wick W, Weller M and Debatin KM: Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 8: 808-815, 2002.
25. Klüttermann K, Kachel M, Tunn PU, Klein-Vehne A, Körholz D and Mauz-Körholz C: Drug-induced caspase-3 activation in Ewing tumor cells. Klin Paediatr 215: 194, 2003.
26. Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, Wang HG, Reed JC, Nicholson DW, Alnemri ES, Green DR and Martin SJ: Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J Cell Biol 144: 281-292, 1999.
27. O'Reilly LA, Ekert P, Harvey N, Marsden V, Cullen L, Vaux DL, Hacker G, Magnusson C, Pakusch M, Cecconi F, Kuida K, Strasser A, Huang DC and Kumar S: Caspase-2 is not required for thymocyte or neuronal apoptosis even though cleavage of caspase-2 is dependent on both Apaf-1 and caspase-9. Cell Death Differ 9: 832-841, 2002.
28. Troy CM and Shelanski ML: Caspase-2 redux. Cell Death Differ 10: 101-107, 2003.
29. Creagh EM and Martin SJ: Cell stress-associated caspase activation: intrinsically complex? Sci STKE, pp. 11, 2003.
30. Keane MM, Ettenberg SA, Nau MM, Russell EK and Lipkowitz S: Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 59: 734-741, 1999.
31. Schmelz K, Wieder T, Tamm I, Muller A, Essmann F, Geilen CC, Schulze-Osthoff K, Dorken B and Daniel PT: Tumor necrosis factor alpha sensitizes malignant cells to chemotherapeutic drugs via the mitochondrial apoptosis pathway independently of caspase-8 and NF-kappaB. Oncogene 23: 6743-6759, 2004.